Downregulation of testicular function in the goat by altrenogest.
Altrenogest
Castration
Downregulation
Goat
Gonadal function
Journal
BMC veterinary research
ISSN: 1746-6148
Titre abrégé: BMC Vet Res
Pays: England
ID NLM: 101249759
Informations de publication
Date de publication:
04 May 2021
04 May 2021
Historique:
received:
29
12
2020
accepted:
18
03
2021
entrez:
5
5
2021
pubmed:
6
5
2021
medline:
9
9
2021
Statut:
epublish
Résumé
The present study investigated whether the administration of the progestin altrenogest provides noninvasive, temporary, and reversible suppression of gonadal function in the goat as a potential alternative to chirurgical castration, which is related with irreversibility, risks of complications till death of the animal and welfare issues. Eight sexually mature Peacock goats were randomly divided into two groups. The experimental group was administered altrenogest (0.088 mg/kg) orally once daily for 7 weeks. The remaining four goats received an oral glucose solution and served as the control group. After completing the administration period, the reversibility of the medication was evaluated for another 7 weeks (observation phase). The treatment effects were assessed by clinical examination; ultrasound examination of the testes, including one-dimensional grayscale analysis, blood testosterone levels, analysis of semen parameters and libido. At the end of the observation period, the animals were castrated and the testicles were examined histologically. Altrenogest treatment had no significant effect on the physical development of the goats, the sonographic appearance of the testes, the gray values measured in the ultrasound images, or the blood testosterone levels. The effects of treatment on the testicular and semen parameters varied widely in the experimental animals; the testicle volume was significantly lower and the number of pathologically altered sperm in the ejaculate was significantly higher in treated animals. These findings indicate that daily altrenogest administration at a dose of 0.088 mg/kg does not reliably suppress gonadal function in the goat.
Sections du résumé
BACKGROUND
BACKGROUND
The present study investigated whether the administration of the progestin altrenogest provides noninvasive, temporary, and reversible suppression of gonadal function in the goat as a potential alternative to chirurgical castration, which is related with irreversibility, risks of complications till death of the animal and welfare issues. Eight sexually mature Peacock goats were randomly divided into two groups. The experimental group was administered altrenogest (0.088 mg/kg) orally once daily for 7 weeks. The remaining four goats received an oral glucose solution and served as the control group. After completing the administration period, the reversibility of the medication was evaluated for another 7 weeks (observation phase). The treatment effects were assessed by clinical examination; ultrasound examination of the testes, including one-dimensional grayscale analysis, blood testosterone levels, analysis of semen parameters and libido. At the end of the observation period, the animals were castrated and the testicles were examined histologically.
RESULTS
RESULTS
Altrenogest treatment had no significant effect on the physical development of the goats, the sonographic appearance of the testes, the gray values measured in the ultrasound images, or the blood testosterone levels. The effects of treatment on the testicular and semen parameters varied widely in the experimental animals; the testicle volume was significantly lower and the number of pathologically altered sperm in the ejaculate was significantly higher in treated animals.
CONCLUSION
CONCLUSIONS
These findings indicate that daily altrenogest administration at a dose of 0.088 mg/kg does not reliably suppress gonadal function in the goat.
Identifiants
pubmed: 33947415
doi: 10.1186/s12917-021-02845-6
pii: 10.1186/s12917-021-02845-6
pmc: PMC8097835
doi:
Substances chimiques
Contraceptive Agents, Male
0
altrenogest
2U0X0JA2NB
Testosterone
3XMK78S47O
Trenbolone Acetate
RUD5Y4SV0S
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
183Références
Andrologia. 2015 Apr;47(3):354-9
pubmed: 24684217
Theriogenology. 1996 Jul 15;46(2):345-57
pubmed: 16727903
Reprod Domest Anim. 2009 Feb;44(1):37-43
pubmed: 18507800
Anim Reprod Sci. 1999 Oct 31;57(1-2):89-98
pubmed: 10565441
J Anim Sci. 1985 Dec;61(6):1441-7
pubmed: 4086393
Theriogenology. 1997 Jul 1;48(1):99-117
pubmed: 16728111
Theriogenology. 2018 Jul 1;114:7-13
pubmed: 29574307
Theriogenology. 1997 Jul 15;48(2):313-28
pubmed: 16728130
J Zoo Wildl Med. 2006 Mar;37(1):61-3
pubmed: 17312816
BMC Vet Res. 2019 Oct 22;15(1):355
pubmed: 31640772
Tierarztl Prax Ausg G Grosstiere Nutztiere. 2016 Jun 16;44(3):171-8
pubmed: 27189125
Theriogenology. 1998 Jul 15;50(2):223-8
pubmed: 10734489
Reprod Domest Anim. 2011 Feb;46(1):108-13
pubmed: 20345588
J Anim Sci. 1988 Feb;66(2):470-8
pubmed: 3131291
Reprod Domest Anim. 2011 Aug;46(4):573-8
pubmed: 21092065
Reprod Nutr Dev. 2004 May-Jun;44(3):183-93
pubmed: 15460158
Eur J Pediatr. 1993;152 Suppl 2:S11-4
pubmed: 8101802
J Vet Pharmacol Ther. 2019 Nov;42(6):660-664
pubmed: 31222770
Theriogenology. 1998 Feb;49(3):581-94
pubmed: 10732037
Br Vet J. 1995 Jan-Feb;151(1):101-10
pubmed: 7735866